Ascendis Pharma A/S $ASND Shares Sold by Moore Capital Management LP

Moore Capital Management LP trimmed its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 25.0% during the third quarter, HoldingsChannel reports. The institutional investor owned 90,000 shares of the biotechnology company’s stock after selling 30,000 shares during the period. Moore Capital Management LP’s holdings in Ascendis Pharma A/S were worth $17,893,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jones Financial Companies Lllp lifted its position in Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 83 shares during the last quarter. Quadrant Capital Group LLC purchased a new position in shares of Ascendis Pharma A/S during the third quarter worth about $74,000. Farther Finance Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 115.3% during the third quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock worth $95,000 after purchasing an additional 256 shares during the last quarter. Toth Financial Advisory Corp increased its position in shares of Ascendis Pharma A/S by 33.7% during the third quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 150 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Ascendis Pharma A/S by 15.2% in the 3rd quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 97 shares during the last quarter.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. The Goldman Sachs Group reissued a “buy” rating and issued a $255.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Oppenheimer lifted their price target on Ascendis Pharma A/S from $246.00 to $262.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Wells Fargo & Company boosted their price objective on Ascendis Pharma A/S from $322.00 to $330.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Wedbush increased their price objective on Ascendis Pharma A/S from $240.00 to $273.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Finally, Evercore restated an “outperform” rating and set a $324.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $289.89.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $231.02 on Tuesday. Ascendis Pharma A/S has a fifty-two week low of $124.06 and a fifty-two week high of $248.60. The firm has a 50-day simple moving average of $224.60 and a 200-day simple moving average of $211.59. The company has a market capitalization of $14.32 billion, a price-to-earnings ratio of -52.50 and a beta of 0.43.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The company had revenue of $290.38 million during the quarter, compared to analysts’ expectations of $285.35 million. Equities research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.